Next Article in Journal
The Homuncular Jigsaw: Investigations of Phantom Limb and Body Awareness Following Brachial Plexus Block or Avulsion
Previous Article in Journal
Risk Factors for Same Pathogen Sepsis Readmission Following Hospitalization for Septic Shock
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
J. Clin. Med. 2019, 8(2), 180; https://doi.org/10.3390/jcm8020180

The Effect of Daily Iron Supplementation with 60 mg Ferrous Sulfate for 12 Weeks on Non-Transferrin Bound Iron Concentrations in Women with a High Prevalence of Hemoglobinopathies

1
Food, Nutrition and Health, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada
2
British Columbia Children’s Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada
3
Helen Keller International, Phnom Penh, Cambodia
*
Author to whom correspondence should be addressed.
Received: 20 December 2018 / Revised: 27 January 2019 / Accepted: 31 January 2019 / Published: 3 February 2019
(This article belongs to the Section Hematology)
Full-Text   |   PDF [227 KB, uploaded 3 February 2019]

Abstract

There is a lack of evidence for the safety of untargeted daily iron supplementation in women, especially in countries such as Cambodia, where both anemia and hemoglobinopathies are common. Our aim was to assess serum non-transferrin bound iron (NTBI), a toxic biochemical that accumulates in blood when too much iron is absorbed, in Cambodian women who received daily iron supplements in accordance with the 2016 global World Health Organization (WHO) guidelines. We used fasting venous blood samples that were collected in a 2015 supplementation trial among predominantly anemic Cambodian women (18–45 years). Serum NTBI was measured with use of the FeROS™ eLPI assay (Aferrix Ltd., Tel-Aviv, Israel) in randomly selected sub-groups of women who received 60 mg daily elemental iron as ferrous sulfate (n = 50) or a placebo (n = 50) for 12 weeks. Overall, n = 17/100 (17%) of women had an elevated serum NTBI concentration (≥0.1 μmol/L) at 12 weeks; n = 9 in the Fe group and n = 8 in the placebo group. Elevated serum NTBI concentration was not associated with age, iron supplementation, transferrin saturation or severe hemoglobinopathies (p > 0.05). In this population of women with a high prevalence of hemoglobinopathies, we found that daily iron supplementation was not associated with elevated serum NTBI concentrations at 12 weeks, as compared to placebo. View Full-Text
Keywords: anemia; hemoglobinopathy; iron; non-transferrin bound iron; supplementation; toxicity; transferrin saturation anemia; hemoglobinopathy; iron; non-transferrin bound iron; supplementation; toxicity; transferrin saturation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Steele, S.L.; Kroeun, H.; Karakochuk, C.D. The Effect of Daily Iron Supplementation with 60 mg Ferrous Sulfate for 12 Weeks on Non-Transferrin Bound Iron Concentrations in Women with a High Prevalence of Hemoglobinopathies. J. Clin. Med. 2019, 8, 180.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top